Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data

References

• Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622–1636. doi:10.1016/S0140-6736(18)30481-1
   PubMed Web of Science ®Google Scholar
• Anon. Number of people with MS | Atlas of MS. Available from: https://www.atlasofms.org/map/global/epidemiology/number-of-people-with-ms. Accessed January 17, 2022.
   Google Scholar
• Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022–1024. doi:10.1212/WNL.0000000000000768
   PubMed Web of Science ®Google Scholar
• McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765–779. doi:10.1001/jama.2020.26858
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286. doi:10.1212/WNL.0000000000000560
   PubMed Web of Science ®Google Scholar
• Ontaneda D. Progressive multiple sclerosis. Contin Minneap Minn. 2019;25(3):736–752.
   PubMedGoogle Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. doi:10.1016/S1474-4422(17)30470-2
   PubMed Web of Science ®Google Scholar
• Stys PK, Zamponi GW, van Minnen J, Geurts JJG. Will the real multiple sclerosis please stand up? Nat Rev Neurosci. 2012;13(7):507–514. doi:10.1038/nrn3275
   PubMed Web of Science ®Google Scholar
• Almuslehi MSM, Sen MK, Shortland PJ, Mahns DA, Coorssen JR. CD8 T-cell recruitment into the central nervous system of cuprizone-fed mice: relevance to modeling the etiology of multiple sclerosis. Front Cell Neurosci. 2020;14:43. doi:10.3389/fncel.2020.00043
   PubMed Web of Science ®Google Scholar
• ’t Hart BA, Luchicchi A, Schenk GJ, Stys PK, Geurts JJG. Mechanistic underpinning of an inside-out concept for autoimmunity in multiple sclerosis. Ann Clin Transl Neurol. 2021;8(8):1709–1719. doi:10.1002/acn3.51401
   PubMed Web of Science ®Google Scholar
• Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296–301. doi:10.1126/science.abj8222
   PubMed Web of Science ®Google Scholar
• Croxford JL, Olson JK, Miller SD. Epitope spreading and molecular mimicry as triggers of autoimmunity in the Theiler’s virus-induced demyelinating disease model of multiple sclerosis. Autoimmun Rev. 2002;1(5):251–260. doi:10.1016/S1568-9972(02)00080-0
   PubMedGoogle Scholar
• Titus HE, Chen Y, Podojil JR, et al. Pre-clinical and clinical implications of ‘inside-out’ vs. ‘outside-in’ paradigms in multiple sclerosis etiopathogenesis. Front Cell Neurosci. 2020;14:599717. doi:10.3389/fncel.2020.599717
   PubMed Web of Science ®Google Scholar
• Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545–558. doi:10.1038/nri3871
   PubMed Web of Science ®Google Scholar
• Tobin WO, Kalinowska-Lyszczarz A, Weigand SD, et al. Clinical correlation of multiple sclerosis immunopathologic subtypes. Neurology. 2021;97(19):e1906–e1913. doi:10.1212/WNL.0000000000012782
   PubMed Web of Science ®Google Scholar
• Lassmann H. Cortical lesions in multiple sclerosis: inflammation versus neurodegeneration. Brain. 2012;135(Pt 10):2904–2905. doi:10.1093/brain/aws260
   PubMed Web of Science ®Google Scholar
• Koch-Henriksen N, Magyari M. Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol. 2021;17(11):676–688. doi:10.1038/s41582-021-00556-y
   PubMed Web of Science ®Google Scholar
• Kalincik T, Diouf I, Sharmin S, et al. Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years. Neurology. 2021;96(5):e783–e797. doi:10.1212/WNL.0000000000011242
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Hafler DA, Lucchinetti CF. Multiple sclerosis—a quiet revolution. Nat Rev Neurol. 2015;11(3):134–142. doi:10.1038/nrneurol.2015.14
   PubMed Web of Science ®Google Scholar
• Cree BAC, Hollenbach JA, Bove R, et al.; University of California, San Francisco MS-EPIC Team. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019;85(5):653–666. doi:10.1002/ana.25463
   PubMed Web of Science ®Google Scholar
• Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol. 2019;18(10):973–980. doi:10.1016/S1474-4422(19)30151-6
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Vaughn CB, Eckert S, Zivadinov R, Weinstock-Guttman B. Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opin Drug Saf. 2020;19(9):1121–1142. doi:10.1080/14740338.2020.1805430
   PubMed Web of Science ®Google Scholar
• Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019;15(5):287–300. doi:10.1038/s41582-019-0170-8
   PubMed Web of Science ®Google Scholar
• Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014;75(1):43–49. doi:10.1002/ana.24018
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655–661. doi:10.1212/WNL.43.4.655
   PubMed Web of Science ®Google Scholar
• Haghikia A, Hohlfeld R, Gold R, Fugger L. Therapies for multiple sclerosis: translational achievements and outstanding needs. Trends Mol Med. 2013;19(5):309–319. doi:10.1016/j.molmed.2013.03.004
   PubMed Web of Science ®Google Scholar
• Schweitzer F, Laurent S, Fink GR, et al. Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis. J Neurol. 2021;268:2379–2389.
   PubMed Web of Science ®Google Scholar
• Mills EA, Mao-Draayer Y. Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients. Mult Scler. 2018 Jul;24(8):1014-1022.
   Google Scholar
• Winkelmann A, Loebermann M, Reisinger EC, Hartung H-P, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol. 2016;12(4):217–233. doi:10.1038/nrneurol.2016.21
   PubMed Web of Science ®Google Scholar
• Barry B, Erwin AA, Stevens J, Tornatore C. Fingolimod rebound: a review of the clinical experience and management considerations. Neurol Ther. 2019;8(2):241–250. doi:10.1007/s40120-019-00160-9
   PubMed Web of Science ®Google Scholar
• Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809. doi:10.1177/1756286419837809
   Web of Science ®Google Scholar
• Zhang Y, Salter A, Wallström E, Cutter G, Stüve O. Evolution of clinical trials in multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286419826547. doi:10.1177/1756286419826547
   Web of Science ®Google Scholar
• Tur C, Kalincik T, Oh J, et al. Head-to-head drug comparisons in multiple sclerosis: urgent action needed. Neurology. 2019;93(18):793–809. doi:10.1212/WNL.0000000000008319
   PubMed Web of Science ®Google Scholar
• Trojano M, Tintore M, Montalban X, et al. Treatment decisions in multiple sclerosis - insights from real-world observational studies. Nat Rev Neurol. 2017;13(2):105–118. doi:10.1038/nrneurol.2016.188
   PubMed Web of Science ®Google Scholar
• Zhang H, Desai NN, Olivera A, et al. Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol. 1991;114(1):155–167. doi:10.1083/jcb.114.1.155
   PubMed Web of Science ®Google Scholar
• Kihara Y, Maceyka M, Spiegel S, Chun J. Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br J Pharmacol. 2014;171(15):3575–3594. doi:10.1111/bph.12678
   PubMed Web of Science ®Google Scholar
• Rosen H, Germana Sanna M, Gonzalez-Cabrera PJ, Roberts E. The organization of the sphingosine 1-phosphate signaling system. Curr Top Microbiol Immunol. 2014;378:1–21. doi:10.1007/978-3-319-05879-5_1
   PubMed Web of Science ®Google Scholar
• Kunkel GT, Maceyka M, Milstien S, Spiegel S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013;12(9):688–702. doi:10.1038/nrd4099
   PubMed Web of Science ®Google Scholar
• Cartier A, Hla T. Sphingosine 1-phosphate: lipid signaling in pathology and therapy. Science. 2019;366(6463):eaar5551. doi:10.1126/science.aar5551
   PubMed Web of Science ®Google Scholar
• Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22(1):50–60. doi:10.1016/j.tcb.2011.09.003
   PubMed Web of Science ®Google Scholar
• Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs. 2015;29(7):565–575. doi:10.1007/s40263-015-0261-z
   PubMed Web of Science ®Google Scholar
• Edmonds Y, Milstien S, Spiegel S. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling. Pharmacol Ther. 2011;132(3):352–360. doi:10.1016/j.pharmthera.2011.08.004
   PubMed Web of Science ®Google Scholar
• Pérez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis. Drugs. 2021;81(9):985–1002. doi:10.1007/s40265-021-01528-8
   PubMed Web of Science ®Google Scholar
• Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurother J Am Soc Exp Neurother. 2017;14(4):859–873.
   Google Scholar
• McGinley MP, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet. 2021;398(10306):1184–1194. doi:10.1016/S0140-6736(21)00244-0
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue E-W, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. doi:10.1056/NEJMoa0909494
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415. doi:10.1056/NEJMoa0907839
   PubMed Web of Science ®Google Scholar
• Chitnis T, Arnold DL, Banwell B, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018;379(11):1017–1027. doi:10.1056/NEJMoa1800149
   PubMed Web of Science ®Google Scholar
• Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–1273. doi:10.1016/S0140-6736(18)30475-6
   PubMed Web of Science ®Google Scholar
• Cohen JA, Comi G, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18(11):1021–1033. doi:10.1016/S1474-4422(19)30238-8
   PubMed Web of Science ®Google Scholar
• Comi G, Kappos L, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009–1020. doi:10.1016/S1474-4422(19)30239-X
   PubMed Web of Science ®Google Scholar
• Brossard P, Derendorf H, Xu J, et al. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013;76(6):888–896. doi:10.1111/bcp.12129
   PubMed Web of Science ®Google Scholar
• Brossard P, Scherz M, Halabi A, et al. Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration. J Clin Pharmacol. 2014;54(2):179–188. doi:10.1002/jcph.244
   PubMed Web of Science ®Google Scholar
• Reyes M, Hoch M, Brossard P, Dingemanse J. Effects of ethnicity and sex on the pharmacokinetics and pharmacodynamics of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod: a clinical study in Japanese and Caucasian subjects. Pharmacology. 2014;94(5–6):223–229. doi:10.1159/000368837
   PubMed Web of Science ®Google Scholar
• Anon. Ponesimod. In: Drugs and Lactation Database (Lactmed). Bethesda (MD): National Library of Medicine (US); 2006. Available from: http://www.ncbi.nlm.nih.gov/books/NBK575381/. Accessed January 20, 2022.
   Google Scholar
• D’Ambrosio D, Steinmann J, Brossard P, Dingemanse J. Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations. Immunopharmacol Immunotoxicol. 2015;37(1):103–109. doi:10.3109/08923973.2014.993084
   PubMed Web of Science ®Google Scholar
• Olsson T, Boster A, Fernández Ó, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J. Neurol. Neurosurg. Psychiatry. 2014;85(11):1198–1208. doi:10.1136/jnnp-2013-307282
   PubMed Web of Science ®Google Scholar
• Freedman MS, Pozzilli C, Havrdova EK, et al. Long-term efficacy and safety of ponesimod, an oral S1P1 receptor modulator: results from randomized phase II core and extension studies in relapsing-remitting multiple sclerosis (1752). Neurology. 2020;94(15 Supplement).
   PubMed Web of Science ®Google Scholar
• Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol. 2021;78(5):558–567. doi:10.1001/jamaneurol.2021.0405
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452. doi:10.1212/WNL.33.11.1444
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Tomic D, Bright JR, Havrdová E. ‘No evident disease activity’: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler. 2017;23(9):1179–1187. doi:10.1177/1352458517703193
   PubMed Web of Science ®Google Scholar
• Pouzol L, Piali L, Bernard CC, et al. Therapeutic potential of ponesimod alone and in combination with dimethyl fumarate in experimental models of multiple sclerosis. Innov Clin Neurosci. 2019;16(3–4):22–30.
   PubMedGoogle Scholar
• Kappos L, Lindenstrom E, Freedman MS, et al. The POINT study: a randomized, double-blind, parallel-group, add-on, superiority phase 3 study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate. Mult Scler. 2018;24(Suppl 2):271.
   Google Scholar